Timeline
-
1963
Establishment of BD Mérieux
-
1967
Launch by BD Mérieux of a fibrometer
-
1969
The first toxoplasmosis detection kit and launch of miniaturized API® 20E strip
-
1972
国产微拍福利Production and sale of the first ready-to-use culture media in Petri plates.
-
1974
Alain Mérieux takes control of BD Mérieux, which becomes bioMérieux.
-
1974
Launch of the Slidex®国产微拍福利 Meningitis kit.
-
1979
ATB™ strip
-
1985
First HIV screening test: VIRONOSTIKA® HIV anti-HTLV-III by Organon Teknika*
-
1986
Acquisition of Api Systems (La Balme, France).
-
1988
Acquisition of Vitek Systems (United States)
-
1989
Development of chromogenic media
-
1990
国产微拍福利Acquisition of the BOOM extraction and NASBA amplification technologies for molecular diagnostics.
-
1991
Launch of the VIDAS®国产微拍福利 with 8 initial kits
-
1992
VIDAS®国产微拍福利 automated immunoassay platform adapted for industrial applications.
-
1995
VIDAS® D-Dimer Exclusion™
-
1997
Launches of BacT/ALERT® 3D and VITEK® 2
19971997
Launches of BacT/ALERT® 3D and VITEK® 2
- BacT/ALERT® 3D an advanced automated system for microbial detection in blood and sterile body fluid samples from Organon Teknika*
- VITEK® 2 an automated identification and antibiotic susceptibility testing system for bacteria and fungi
-
2001
Acquisition of OrganonTeknika (Akzo Nobel, Netherlands).
-
2002
NucliSENS EasyQ® and NucliSENS EasyQ® HIV-1
-
2004
国产微拍福利bioMérieux is listed on the stock exchange.
-
2004
Launches of TEMPO® and VITEK® 2 Compact
-
2006
Acquisition of Bacterial Barcodes (USA)
-
2007
国产微拍福利Acquisition of Biomedics (Spain) and of BTF (Australia)
-
2008
国产微拍福利Joint ventures and Acquisitions
20082008
Joint ventures and Acquisitions
- Acquisition of AB BIODISK (Sweden), a company internationally recognized for its antimicrobial resistance testing range and particular expertise in susceptibility testing of fastidious and unusual organisms.
- Acquisition of AviaraDx (USA), now bioTheranostics, a specialist in the molecular diagnosis of tumorous tissues.
- Acquisition of PML Microbiologicals (USA), a company devoted to the development and production of culture media.
- Joint venture with Sysmex, the Japanese market leader in the field of in vitro diagnostics.
- Joint venture with Shanghai Kehua Bio-engineering (China) for the production of microplate immunoassays.
-
2009
Launch of PREVI® Color Gram
-
2010
国产微拍福利Acquisition of Meikang Biotech and of Shanghai Zenka Biotechnology.
-
2010
Launch of Myla® middleware
20102010
Launch of Myla® middleware
- Myla® middleware is a software solution for the optimization of laboratory workflow and clinical information management. It is a complement to FMLA® (Full Microbiology Lab Automation).
- BacT/ALERT® 3D Dual-T, a microbial detection system used for sterility testing in the biopharmaceutical industry.
-
2011
Acquisition of AES Laboratoire (France).
-
2011
Acquisition of ARGENE (France)
-
2011
国产微拍福利Launch of VITEK® MS
20112011
Launch of VITEK® MS
- Launch of VITEK® MS (used in association with the VITEK® 2 system) an automated mass spectrometry microbial identification system for clinical and industrial applications.
- First bioNexia® rapid tests commercialized by bioMérieux.
- Inauguration of the laboratory of the future at Marcy l’Étoile, France (over 1,000 visits from biologists and scientists in a year). Development of a similar unit in Saint Louis, Missouri (USA). The laboratories enable discussions to align bioMérieux’s future products and services with customer needs.
-
2012
Acquisition of RAS (India) and partnership with Quanterix
-
2013
国产微拍福利FDA approval of novel molecular test THxID™-BRAF
-
2013
VIDAS® 3
-
2014
Acquisition of BioFire Diagnostics Inc.
-
2014
国产微拍福利FDA clearance for the FilmArray® Gastrointestinal (GI) Panel
20142014
FDA clearance for the FilmArray® Gastrointestinal (GI) Panel
The 22-target FilmArray® GI Panel1 allows a syndromic approach2国产微拍福利 to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test.
A test panel is a predetermined group of medical tests used as an aid in the diagnosis and treatment of diseases.
The syndromic approach is based on analyzing a syndrome (i.e. a set of symptoms) and, with a single reagent, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses, bacteria or parasites.
-
2014
Launch of CE-marked VIRTUO™
-
2015
Strategic partnership between bioMérieux and COPAN (Italia)
20152015
Strategic partnership between bioMérieux and COPAN (Italia)
Strategic partnership in clinical microbiology laboratory automation between bioMérieux and COPAN. Leading manufacturer of innovative pre-analytic solutions, COPAN grants distribution rights for its automated platforms WASP® and WASPLab™.
-
2015
Launch of bioMérieux EPISEQ™
-
2015
Launch of GENE-UP®
-
2016
Acquisition of Applied Maths (Belgium)
-
2016
FilmArray® Torch is FDA cleared with all 4 existing FilmArray®国产微拍福利 Panels and the system gets CE marked
20162016
FilmArray® Torch is FDA cleared with all 4 existing FilmArray®国产微拍福利 Panels and the system gets CE marked
The FilmArray®国产微拍福利 Torch platform is FDA-cleared for use with the Respiratory, Blood Culture Indentification, Gastrointestinal and Meningitis/Encephalitis panels. It provides up to six times more sample throughput per square foot of benchtop space.
-
2016
Acquisition of Hyglos (Germany)
-
2016
Launch of EVISIGHT™ COMPACT
-
2016
Launch of EMAG®
20162016
Launch of EMAG®
A new molecular biology platform for the extraction of nucleic acids (DNA, RNA) that builds on the quality, robustness and ease of use that have made the NucliSENS® easyMAG® platform so successful. eMAG® features automation from the primary sample tube, greater traceability and higher throughput, in addition to an unparalleled degree of flexibility, not previously available on an automated system for the extraction of nucleic acids.
-
2016
Moving of the Campus de l’Étoile
-
2017
FDA clearance for VIDAS® B•R•A•H•M•S PCTTM
-
2017
FDA 510(k) clearance for the BacT/ALERT® VIRTUO™ automated blood culture system
20172017
FDA 510(k) clearance for the BacT/ALERT® VIRTUO™ automated blood culture system
BacT/ALERT®国产微拍福利 VIRTUO™ is the first continuously-monitoring blood culture microbial detection system to offer “Load & Go” technology, helping labs to streamline their workflow. It is now commercially available in countries that recognize CE marking and in the United States.
-
2017
FDA clearance for BIOFIRE® FILMARRAY® RP2, CE marked for RP2 plus
20172017
FDA clearance for BIOFIRE® FILMARRAY® RP2, CE marked for RP2 plus
The Respiratory BIOFIRE® FILMARRAY® 2 (RP2) panel, enriched version of the Respiratory BIOFIRE® FILMARRAY® panel, tests in 45 minutes 21 pathogens (17 viruses and 4 bacteria) responsible for respiratory tract infections. It incorporates an additional pathogen, Bordetella parapertussis国产微拍福利, one of the causative agents of pertussis or whooping cough.
The BIOFIRE® FILMARRAY® RP2 plus includes one additional pathogen: Middle East Respiratory Syndrome coronavirus (MERS-CoV).
-
2017
FDA clearance for expanded pathogen identification capability on VITEK® MS
20172017
FDA clearance for expanded pathogen identification capability on VITEK® MS
VITEK®国产微拍福利 MS, rapid pathogen identification, has received 510(k) clearance from the FDA for the expanded identification of mycobacteria, Nocardia and moulds.
- A database of more than 15,000 strains
- For the first time, enables the safe identification of the Mycobacterium tuberculosis (TB) group
-
2017
FDA clearance for RAPIDEC® CARBA NP test
-
2017
国产微拍福利Alexandre Mérieux appointed Chairman and CEO of bioMérieux
20172017
国产微拍福利Alexandre Mérieux appointed Chairman and CEO of bioMérieux
国产微拍福利After serving as CEO of bioMérieux for the last three years, Alexandre Mérieux succeeds Jean-Luc Bélingard, who had been Chairman of the Company since 2010.
As the next Mérieux generation takes up the position of Chairman and CEO, this appointment marks the continuity of the family’s role in the Company.
-
2018
国产微拍福利Acquisition of Astute Medical (United-States)
20182018
Acquisition of Astute Medical (United-States)
Dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers.
Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI).
This acquisition follows a development and commercialization partnership signed in 2015 with Astute to develop and market the NEPHROCHECK® test, for the VIDAS® automated immunoassay system. It reinforces bioMérieux’s offering of High Medical Value immunoassay biomarkers.
Fruitful partnership developed in 2015 between Astute Medical and bioMérieux when Astute granted bioMérieux a license to develop and market the NEPHROCHECK® test for the VIDAS®国产微拍福利 automated immunoassay system
-
2018
ENDOZYME® II GO launch
-
2018
CE mark for expanded VITEK® MS database
20182018
CE mark for expanded VITEK® MS database
The latest additions to the database used by this automated mass spectrometry microbial identification system allows the identification of :
- Brucella, which is often difficult for laboratory staff to recognize
- Emerging antibiotic-resistant pathogens such as Candida auris, Elizabethkingia anophelis and other clinically relevant bacteria.
This innovative solution further improves the performance of the VITEK® MS system by adding 272 new species to its database, including 217 bacteria species and 55 fungal species.
-
2018
国产微拍福利Acquisition of a majority stake in Hybiome (China)
20182018
国产微拍福利Acquisition of a majority stake in Hybiome (China)
The Chinese Company Suzhou Hybiome Biomedical Engineering Co.Ltd is specialized in automated immunoassay tests.
Founded in 2009, the company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the China Food and Drug Administration (CFDA).
-
2018
国产微拍福利Launch of the BIOFIRE® FILMARRAY® Pneumonia Panels
20182018
Launch of the BIOFIRE® FILMARRAY® Pneumonia Panels
The BIOFIRE® FILMARRAY® Pneumonia panel received 510 (k) clearance from the Food and Drug Administration (FDA).
The BIOFIRE® FILMARRAY® Pneumonia Panel plus received the CE-Mark.
These panels aid in the diagnosis of lower respiratory tract infections.
-
2019
国产微拍福利Acquistion of Invisible Sentinel (United-States)
-
2020
Launch of the SARS-COV-2 R-GENE® test
-
2020
BIOFIRE® COVID-19 test
-
2020
CE marking of VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG
-
2020
CE marking of BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2
-
2020
Launch of BIOFIRE® MYCOPLASMA
- 1963
- 1967
- 1969
- 1972
- 1974
- 1979
- 1985
- 1986
- 1988
- 1989
- 1990
- 1991
- 1992
- 1995
- 1997
- 2001
- 2002
- 2004
- 2006
- 2007
- 2008
- 2009
- 2010
- 2011
- 2012
- 2013
- 2014
- 2015
- 2016
- 2017
- 2018
- 2019
- 2020